Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04162795 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies
A Phase 4 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 468
- Enrollment target
NCT04162795: Completed Phase 4 study, sponsored by Bayer.
NCT04162795 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 468 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04162795, a Phase 4 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 468 participants
- Enrollment target
Study Summary
In this study, researchers were primarily interested in evaluating the level of agreement of cooling sensation provided by this chewable, flavored, allergy medicine. Participants joining this study received one test drug tablet and were asked to chew completely before swallowing the drug. A questionnaire was used to collect the feedback from participants. The study involved only one (1) visit and participant stayed in this study for about 60-75 minutes to evaluate the cooling sensation as well as other sensory attributes perceived in the mouth, nose and throat.
Primary Outcome
Participants were asked to response to question "the product provides a cooling sensation" using a 5 point agreement scale (range from 1=strongly disagree to 5=strongly agree). Selection of the top 2 choices (strongly agree and somewhat agree) from the scale was considered as agreement of perception of the sensation.
Interventions
- DRUG Loratadine (Claritin, BAY76-2211)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2019-11-12 |
| Est. Completion | 2019-11-13 |
| Phase | Phase 4 |
What the finished NCT04162795 record still lists
NCT04162795 is an interventional study that assigns participants to a tested intervention. The registered 468 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 1 intervention - of which Loratadine (Claritin, BAY76-2211) is the first listed.
NCT04162795 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04162795 about?
NCT04162795 is a clinical study titled "A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies". In this study, researchers were primarily interested in evaluating the level of agreement of cooling sensation provided by this chewable, flavored, allergy medicine. Participants joining this study received one test drug tablet and were asked to chew completely before swallowing the drug. A question...
What is the current status of trial NCT04162795?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 468 participants. The study started on 2019-11-12. Estimated completion is 2019-11-13.
What interventions are being tested in trial NCT04162795?
The interventions under investigation include: Loratadine (Claritin, BAY76-2211) (DRUG).
Who is sponsoring clinical trial NCT04162795?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04162795's enrollment target sits among peer trials
468 182nd of 2000 higher than 1,819 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03124303 · 468 participants
Interventions for Postoperative Delirium: Biomarker-3
- NCT03901924 · 468 participants · NA
Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
- NCT04482309 · 468 participants · Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
- NCT05357170 · 468 participants
Microbiome Dysfunction in Surgical Intensive Care Unit Survivors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI